ClinicalTrials.gg
WithdrawnNCT05571540Updated Nov 30, 2022

Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

A Phase 1/2 interventional study of U-CAR-T Cells (LstCAR019) in B-cell Acute Lymphoblastic Leukemia and B-ALL, sponsored by Kunming Hope of Health Hospital. Withdrawn at 1 site in China. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Kunming Hope of Health Hospital · Phase 1/2, Interventional, and Treatment

How we know

Why this study was withdrawn
The PI decides to stop.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
2 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Burkitt Lymphoma with a site in China — 58 open to participants now, 62 under way, 4 of them phase 3. Burkitt Lymphoma · China.

Enrollment
97th of 100
0 · median 24
Started
2022
with 11 others
Phase 1/2
21 of 102
9 open now
Registered
45th of 102
by date

Among the 102 studies in Burkitt Lymphoma with a site in China, this one is the 97th largest by enrollment of the 100 interventional ones that give a count, is one of 12 that started in 2022, is one of 21 in phase 1/2, and was the 45th registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

58 of the 102 studies in Burkitt Lymphoma with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Burkitt Lymphoma with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, single-center, open-labeled clinical study to evaluate the safety and efficacy of LstCAR019 injection for patients with relapsed/refractory(r/r) B-cell Acute Lymphoblastic Leukemia(B-ALL).

Read the detailed description

Although the anti-CD19 CAR-T cell therapies have gained significant clinical outcome in patients with r/r B-ALL,autologous CAR-T is not feasible for some patients. To make further improvement, the investigators are going to conduct a clinical trial using universal CAR-T cells(LstCAR019) targeting CD19 for r/r B-ALL patients.

After enrollment, patients will get a 3-5 days lymphodepletion therapy, then the LstCAR019 will be infused by vein. Subjects will be followed for safety and efficacy up to 12 weeks. For those with a durable remission 12 weeks after infusion, the follow-up will last for at least 12 months for disease control.

03

Conditions studied

  • B-cell Acute Lymphoblastic Leukemia
  • B-ALL

Browse trials for

Keywords

  • universal CAR-T
  • CD19
04

Who can participate

Ages eligible
2 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 2-75 years;
  2. A definite diagnosis of B-ALL and a percentage of primitive/naive lymphocytes >5% in bone marrow at baseline (flow cytometry);
  3. CD19 expression was positive in bone marrow or peripheral blood tumor cells;
  4. score 0-2 points;
  5. Expected survival time ≥3 months;
  6. Adequate liver, kidney, heart and lung function;
  7. Patients who have recovered from acute toxic effects of prior chemotherapy should be excluded from the trial at least one week apart;
  8. Women of childbearing age have negative blood pregnancy test before the start of the trial, and agree to take effective measures during the trial until the last follow-up; male subjects with partners of agree to take effective contraceptive measures during the trial until the last follow-up;
  9. Voluntarily sign the .

Exclusion criteria

Exclusion Criteria:

  1. Presence of other concurrent active ;
  2. People with severe mental disorders;
  3. A history of any of the following genetic disorders, such as Fanconi anemia, Schu-Day syndrome, Gerstmann syndrome, or any other known bone marrow failure syndrome;
  4. Acute of grade II-IV or extensive chronic GVHD;
  5. Had grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically prominent heart disease within one year prior to enrollment;
  6. The presence of any indwelling catheter or drainage (e.g., percutaneous nephrostomy, indwelling catheter, bile drainage, or pleural/peritoneal/pericardial catheter), except for patients who are permitted to use dedicated central venous catheters;
  7. A history or disease of the central nervous system(CNS), such as seizure disease, cerebrovascular ischemia/bleeding, dementia, cerebellar disease, or any disease involving the CNS;
  8. (HIV) seropositivity; surface antigen positive or hepatitis B core antibody positive, and HBV-DNA positive; Patients with (HCV-RNA quantitative test results positive); Or the presence of other serious active viral or bacterial infections or uncontrolled systemic fungal infections;
  9. Patients with severe history of allergy or allergic constitution;
  10. A history of autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) leading to end-organ damage or requiring systemic /systemic disease modulating drugs within the past 2 years;
  11. Had or is suffering from interstitial lung disease (e.g., pneumonia, pulmonary fibrosis);
  12. Had undergone other clinical trials in the 4 weeks prior to participating in this trial;
  13. Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan;
  14. For patients with cyclophosphamide and fludarabine chemotherapy;
  15. Subjects requiring systemic therapy (prednisone ≥5mg/ day or equivalent dose of another corticosteroid) or other immunosuppressive agents within 1 month after LstCAR019 cell reinfusion, except for adverse events;
  16. Receiving donor lymphocyte infusion within 6 weeks before enrollment;
  17. Pregnant and lactating women;
  18. Any other condition that the investigator deemed inappropriate for inclusion.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    U-CAR-T Cells (LstCAR019)

    Subjects who meet the enrollment conditions will receive intravenous infusion of U-CAR-T Cells (LstCAR019) after lymphodepletion.

    Biological: U-CAR-T Cells (LstCAR019)

Interventions

  • BiologicalU-CAR-T Cells (LstCAR019)

    LstCAR019 will be administered by vein. The trial includes two portions. The first portion is a"3+3"dose escalation study, in which three dose groups are set:Dose level one: 1×10\^6 cells/kg;Dose level two: 2×10\^6 cells/kg;Dose level three: 5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the"3+3"dose escalation study. Twelve subjects will get infusion of LstCAR019 at the best dose verified in the first portion.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Neurotoxicity and/or CRS≥G3.

    Time frame: Up to 28 days after LstCAR019 infusion

  2. Incidence of Treatment Related adverse events (AEs)

    The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included.

    Time frame: Up to 12 months after LstCAR019 infusion

Secondary outcomes

  1. Persistence of CAR-T cells

    The persistence over time of CAR-T cells in the peripheral blood as determined by flow cytometry and qPCR.

    Time frame: Up to 24 weeks after infusion

  2. Objective response rate (ORR)

    Patients who achieve CR(complete response) or CRi after infusion

    Time frame: At 4 ,8 , 12 weeks after infusion

  3. Progression-free survival (PFS)

    Progression-free survival (PFS) is the time between the time a patient with tumor disease receives treatment and the time between the observation of disease progression or death from any cause.

    Time frame: Up to 24 weeks after infusion

  4. Overall survival (OS)

    Overall survival (OS) is the time from randomization to death from any cause.

    Time frame: Up to 24 weeks after infusion

  5. Duration of remission (DOR)

    Duration of remission (DOR) is the time from the first detection of CR or PR to the discovery of PD.

    Time frame: Up to 24 weeks after infusion

07

Study locations

1 site
  • Kunming Hope of Health Hospital
    Kunming, Yunnan 650000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Jan 2024, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2022
First posted
Oct 7, 2022
StartActual
Oct 1, 2022
Primary completionEst.
Jan 31, 2024
CompletionEst.
Oct 31, 2024
Last update
Nov 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05571540
Lead sponsor
Kunming Hope of Health Hospital
Responsible party
Sponsor
First posted
Oct 7, 2022
Start date
Oct 1, 2022
Primary completion
Jan 31, 2024 (estimated)
Completion
Oct 31, 2024 (estimated)
Last update
Nov 30, 2022

Study contacts

Li Li, MD
principal investigator · Kunming Hope of Health Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion